

Department of Pathophysiology and Therapy in Chronic Kidney Disease

Tatsuo Hosoya, *Professor*
Iwao Ohno, *Professor*
Keitaro Yokoyama, *Associate Professor*

Satoru Kuriyama, *Professor*
Kimiyoichi Ichida, *Professor*
Yukio Maruyama, *Assistant Professor*

General Summary

Overview of education and research

This department aims to advance education and research to prevent the onset and development of chronic kidney disease (CKD) and to slow the increase in the number of patients with renal failure. The number of elderly patients undergoing hemodialysis (HD) for renal failure has increased markedly in Japan and has become a critical social and medical economic problem. One solution for this problem is to prevent the onset and progression of CKD and to reduce the number of patients requiring HD.

Another solution is to improve the quality of life for the rehabilitation of patients who have already undergone HD and to promote home HD (HHD) and continuous ambulatory peritoneal dialysis (CAPD) that can be performed at home. Both HHD and CAPD will greatly benefit patients undergoing HD, particularly patients who have difficulty visiting hospitals because of old age or disability. Furthermore, when the Great East Japan Earthquake occurred, it was shown that CAPD could be performed in disaster areas.

Research Activities

Prevention of CKD and its progression

Hyperuricemia has long been suggested to be a risk factor for the onset and progression of CKD, but definitive evidence was lacking, because an antihyperuricemic agent that could reduce uric acid levels effectively and safely in patients with renal dysfunction, such as CKD, was not available. Within the last 3 years, 2 novel antihyperuricemic agents that can be used effectively and safely in patients with renal dysfunction have been developed. The efficacy and safety of one agent, febuxostat, were investigated in patients with CKD IIIb and IV and reported at academic meetings and in a paper. Furthermore, a double-blind multicenter prospective clinical trial (FEATHER study: Febuxostat versus placebo randomized controlled trial regarding reduced renal function in patients with hyperuricemia complicated by chronic kidney disease stage 3) is in progress with more than 400 patients with CKD IIIab and hyperuricemia.

The utility and safety of topiroxostat, another novel antihyperuricemic agent, was investigated in patients with CKD III and hyperuricemia, and its effects on renal function, blood pressure, and albuminuria were examined. The result that albuminuria decreased significantly in patients receiving topiroxostat was reported in a paper. The underlying mechanism of reduced albuminuria is being investigated in basic research, and the effect is being confirmed separately in a panel of primary diseases for renal failure. Furthermore, a

randomized clinical trial to examine the effect of urinary protein loss caused by diabetic nephropathy is in progress.

Efforts to promote CAPD

To promote CAPD, a method of HHD, our department has employed peritoneal dialysis coordinators and had them visit the homes of patients undergoing CAPD to solve the problems presented by the patients and their families. The patients were then asked to answer a questionnaire survey about CAPD; the results were analyzed and presented at academic meetings. Because we believe that HHD by CAPD cannot be promoted without the cooperation of nursing care facilities and health and welfare facilities, CAPD study meetings have been held periodically with colleagues in such facilities near Kashiwa Hospital.

Combination therapy with HD once a week has been tried in patients undergoing CAPD with disturbed peritoneal function or insufficient water removal. A retrospective study and a prospective study (EARTH Study: The study of evaluating adequateness replacement therapy) are ongoing as multicenter collaborative studies to elucidate the effectiveness of the combination therapy. The retrospective study has already been completed and is being prepared for publication, while the prospective study is ongoing.

Check-up and evaluation

Research regarding the onset and development of hyperuricemia and CKD is ongoing. The analysis of the FEATHER study will be completed in March 2016, and a manuscript is being prepared. That topiroxostat reduces albuminuria similarly in a variety of renal diseases has been verified and reported in a paper. Experiments are in progress to elucidate the underlying mechanism in basic studies.

While CAPD has been promoted in patients with renal failure at the Department of Nephrology and Hypertension of our medical school, we hope other institutions will participate in this project and help establish the status of PD coordinators. To this end, we would like to make proposals for fulfillment of the systems for patients undergoing CAPD, such as medical insurance and nursing care insurance.

Publications

Nakayama A¹, Matsuo H¹, Nakaoka H², Nakamura T¹, Nakashima H¹, Takada Y¹, Oikawa Y², Takada T⁴, Sakiyama M¹, Shimizu S¹, Kawamura Y¹, Chiba T¹, Abe J¹, Wakai K², Kawai S⁵, Okada R⁵, Tamura T², Shichijo Y¹, Akashi A¹, Suzuki H¹, Hosoya T¹, Sakurai Y¹, Ichida K⁶, Shinomiya N¹ (¹Natl Def Med Coll, ²Natl Inst Genet, ³Toho Univ Ohashi Med Ctr, ⁴Univ Tokyo Hosp, ⁵Nagoya Univ Grad Sch Med, ⁶Tokyo Univ Pharm Life Sci). Common dysfunctional variants of ABCG2 have stronger impact on hyperuricemia progression than typical environmental risk factors. *Sci Rep*. 2014; **4**: 5227. **Maruyama Y, Taniguchi M (Kyushu Univ), Kazama JJ (Niigata Univ), Yokoyama K,**

Hosoya T, Yokoo T, Shigematsu T (Wakayama Med Univ), Iseki K (Ryukyuu Univ), Tsubakihara Y. A higher serum alkaline phosphatase is associated with the incidence of hip fracture and mortality among patients receiving hemodialysis in Japan. *Nephrol Dial Transplant*. 2014; **29**: 1532-8. **Matsuo H¹, Takada T¹, Nakayaoka A¹, Shimizu T², Sakiyama M¹, Shimizu S¹, Chiba T¹, Nakashima H¹, Nakamura T¹, Takada Y², Sakurai Y¹, Hosoya T¹, Shinomiya N¹, Ichida K⁴** (¹Natl Def Med Coll, ²Midorigaoka Hosp, ³Univ Tokyo, ⁴Tokyo Univ Pharm Life Sci). ABCG2 dysfunction increases the risk of renal overload hyperuricemia. *Nucleosides Nucleotides Nucleic Acids*. 2014; **33**: 266-74.

- Hosoya T, Kimura K¹, Itoh S², Inaba M³, Uchida S⁴, Tomino Y⁵, Makino H⁶, Matsuo O⁷, Yamamoto T⁸, Ohno I, Shibagaki Y, Jimuro S⁹, Imai N¹, Kuwabara M¹⁰, Hayakawa H (St. Marianna Univ Sch Med, ²Tohoku Univ, ³Osaka City Univ, ⁴Teikyo Univ, ⁵Juntendo Univ, ⁶Okayama Univ, ⁷Nagoya Univ, ⁸Hyogo Coll Med, ⁹Univ Tokyo Hosp, ¹⁰Toranomon Hosp).** The effect of febuxostat to prevent a further reduction in renal function of patients with hyperuricemia who have never had gout and are complicated by chronic kidney disease stage 3: study protocol for a multi-center randomized controlled study. *Trials*. 2014; **15**: 26.
- Hosoya T, Ohno I, Nomura S¹, Hisatome I², Uchida S³, Fujimori S³, Yamamoto T⁴, Hara S⁵ (Suzuka Kaisei Hosp, ²Tottori Univ Grad Sch Med Sci, ³Teikyo Univ, ⁴Hyogo Coll Med, ⁵Toranomon Hosp).** Effects of toproxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout. *Clin Exp Nephrol*. 2014; **18**: 876-84.
- Kurashige M, Hanaoka K, Imamura M¹, Udagawa T, Kawaguchi Y, Hasegawa T, Hosoya T, Yokoo T, Maeda S¹ (RIKEN).** A comprehensive search for mutations in the PKD1 and PKD2 in Japanese subjects with autosomal dominant polycystic kidney disease. *Clin Genet*. 2015; **87**: 266-72.
- Sakiyama M¹, Matsuo H¹, Shimizu S¹, Nakashima H¹, Nakayama A¹, Chiba T¹, Naito M², Takada T³, Suzuki H³, Hamajima N³, Ichida K⁴, Shimizu T⁵, Shinomiya N¹ (Natl Def Med Coll, ²Nagoya Univ, ³Univ Tokyo Hosp, ⁴Tokyo Univ Pharm Life Sci, ⁵Midorigaoka Hosp).** A common variant of organic anion transporter 4 (OAT4/SLC22A11) gene is associated with renal underexcretion type gout. *Drug Metab Pharmacokin*. 2014; **29**: 208-10.
- Sakiyama M¹, Matsuo H¹, Chiba T¹, Nakayama A¹, Nakamura T¹, Shimizu S¹, Morita E¹, Fukuda N¹, Nakashima H¹, Sakurai Y¹, Ichida K², Shimizu T³, Shinomiya N¹ (Natl Def Med Coll, ²Tokyo Univ Pharm Life Sci, ³Midorigaoka Hosp).** Common variants of cGKII/PRKG2 are not associated with gout susceptibility. *J Rheumatol*. 2014; **41**: 1395-97.
- Saikawa H, Ichida K (Tokyo Univ Pharm Life Sci), Ohno I, Hosoya T, Yokoo T.** Clinical feature and ABCG2 gene mutation of gouty kidneys diagnosed by abdominal ultrasonography (in Japanese). *Tsufu to Kakusan Taisha*. 2014; **38**: 117-28.
- Kuriyama S, Nakano T (Tokyo Taxation Off Clin Hlth Manage Ctr), Maruyama Y, Sugano N, Takane K, Suetsugu Y, Takahashi Y, Kobayashi C, Nishio S, Takahashi D, Kidoguchi S, Ichida K (Tokyo Univ Pharm Life Sci), Ohno I, Hosoya T, Yokoo T.** Relationship between serum uric acid levels and muscle strength/volume: a new insight from a large-scale survey (in Japanese). *Nihon Jinzo Gakkaiishi*. 2014; **56**: 1260-9.
- Uehara I¹, Kimura T¹, Tanigaki S¹, Fukutomi T¹, Sakai K¹, Shinohara Y², Ichida K², Iwashita M¹, Sakurai H¹ (Kyorin Univ, ²Tokyo Univ Pharm Life Sci).** Paracellular route is the major urate transport pathway across the blood-placental barrier. *Physiol Rep*. 2014; **2**: e12013.
- Nakamura M¹, Sasai N², Hisatome I³, Ichida K¹ (Tokyo Univ Pharm Life Sci, ²Sasai Clin, ³Tottori Univ).** Effects of irbesartan on serum uric acid levels in patients with hypertension and diabetes. *Clin Pharmacol*. 2014; **6**: 79-86.
- Chiba T¹, Matsuo H¹, Kawamura Y¹, Nagamori S², Nishiyama T³, Wei L², Nakayama A¹, Nakamura T¹, Sakiyama M¹, Takada T⁴, Taketani Y⁴, Suma S⁵, Naito M⁶, Oda T⁷, Kumagai H¹, Moriyama Y⁸, Ichida K¹, Shimizu T⁹, Kanai Y², Shinomiya N¹ (Natl Def Med Coll, ²Osaka Univ, ³Univ Tokyo Hosp, ⁴Univ Tokushima Grad Sch, ⁵Nagoya Univ, ⁶Okayama Univ, ⁷Tokyo Univ Pharm Life Sci, ⁸Midorigaoka Hosp).** NPT1/SLC17A1 is a renal urate exporter in humans and its common gain-of-function variant decreases the risk of renal underexcretion gout. *Arthritis Rheumatol*. 2015; **67**: 281-7.
- Chiba T¹, Matsuo H¹, Sakiyama M¹, Nakayama A¹, Shimizu S¹, Wakai K², Suma S³, Nakashima H¹, Sakurai Y¹, Shimizu T¹, Ichida K⁴, Shinomiya N¹ (Natl Def Med Coll, ²Nagoya Univ, ³Midorigaoka Hosp, ⁴Tokyo Univ Pharm Life Sci).** Common variant of ALPK1 is not associated with gout: a replication study. *Hum Cell*. 2015; **28**: 1-4.
- Hasegawa H¹, Shinohara Y¹, Nozaki S¹, Nakamura M¹, Oh K², Namiki O², Suzuki K³, Nakahara A⁴, Miyazawa M⁵, Ishikawa K⁶, Himeno T⁷, Yoshida S⁸, Ueda T⁹, Yamada Y¹⁰, Ichida K¹ (Tokyo Univ Pharm Life Sci, ²Showa Univ, ³Toyohashi Med Ctr, ⁴Miyazaki Univ, ⁵Kochi Hlth Sci Ctr, ⁶Iwate Med Univ, ⁷Brain Attack Ctr Ota Memorial Hosp, ⁸Nara Pref Gen Med Ctr, ⁹Fukui Univ, ¹⁰Aichi Human Serv Ctr).** Hydrophilic-interaction liquid chromatography-tandem mass spectrometric determination of erythrocyte 5-phosphoribosyl 1-pyrophosphate in patients with hypoxanthine-guanine phosphoribosyltransferase deficiency. *J Chromatogr B Analyt Technol Biomed Life Sci*. 2015; **976-7**: 55-60.
- Yokoyama K, Hirakata H (Jpn Red Cross Fukuoka Hosp), Akiba T (Tokyo Women's Med Univ), Fukagawa M (Tokai Univ), Nakayama M (Fukushima Med Univ Sch Med), Sawada K (Akita Univ), Kumagai Y (Kitasato Univ East Hosp Clin Trial Ctr), Block GA (Denver Nephrologists).** Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD. *Clin J Am Soc Nephrol*. 2014; **9**: 543-52.
- Yokoyama K, Akiba T (Tokyo Women's Med Univ), Fukagawa M (Tokai Univ), Nakayama M (Fukushima Med Univ Sch Med), Sawada K (Akita Univ), Kumagai Y (Kitasato Univ East Hosp Clin Trial Ctr), Chertow GM (Stanford Univ), Hirakata H (Jpn Red Cross Fukuoka**

Hosp). Long-term safety and efficacy of a novel iron-containing phosphate binder, JTT-751, in patients receiving hemodialysis. *J Ren Nutr.* 2014; **24**: 261-7.

Tanabe N, Takane K, Yokoyama K, Tanno Y, Yamamoto I, Ohkido I, Yokoo T. Dialysate temperature adjustment as an effective treatment for baroreflex failure syndrome in hemodialysis patient. *BMC Nephrol.* 2014; **15**: 151.

Kobayashi A, Yamamoto I, Nakada Y, Kidoguchi S, Matsuo N, Tanno Y, Ohkido I, Tsuboi N, Yamamoto H, Yokoyama K, Yokoo T. Successful treatment of BK virus nephropathy using therapeutic drug monitoring of mycophenolic acid. *Nephrology (Carlton).* 2014; **19** Suppl 3: 37-41.

Furuya M, Yamamoto I, Kobayashi A, Nakada Y, Sugano N, Tanno Y, Ohkido I, Tsuboi N, Yamamoto H, Yokoyama K, Yokoo T. Plasma cell-rich rejection accompanied by acute antibody-mediated rejection in a patient with ABO-incompatible kidney transplantation. *Nephrology (Carlton).* 2014; **19** Suppl 3: 31-4.

Nakada Y, Yamamoto I, Kobayashi A, Mafune A, Yamakawa T, Matsuo N, Tanno Y, Ohkido I, Yamamoto H, Yokoyama K, Yokoo T. Acute vascular rejection during antituberculosis therapy in a kidney transplant patient. *Nephrology (Carlton).* 2014; **19** Suppl 3: 27-30.

Maruyama Y, Yokoyama K, Nakayama M¹, Higuchi C², Sanaka T², Tanaka Y³, Sakai K³, Mizuiri S³, Otsuka Y, Kuriyama S, Maeba T⁴, Iwasawa H⁵, Nakao T⁵, Hosoya T (Fukushima Med Univ Sch Med, ²Tokyo Women's Med

Univ Med Ctr East, ³Toho Univ, ⁴Asao Kidney Clin, ⁵Tokyo Med Univ); EARTH (Evaluation of the Adequacy of Renal replacement Therapy) study group. Combined therapy with peritoneal dialysis and hemodialysis: a multicenter retrospective observational cohort study in Japan. *Blood Purif.* 2014; **38**: 149-53.

Yokoyama K. New developments in CKD-MBD. New aspects in phosphate binders (in Japanese). *Clinical Calcium.* 2014; **24**: 1815-23.

Akizawa T¹, Akiba T², Hirakata H³, Kinugasa E⁴, Tominaga Y⁵, Fukagawa M⁶, Yokoyama K, Zhang W⁷, Linde PG⁷, Suzuki M⁸ (Showa Univ, ²Tokyo Women's Med Univ, ³Jpn Red Cross Fukuoka Hosp, ⁴Showa Univ North Yokohama Hosp, ⁵Nagoya Daini Red Cross Hosp, ⁶Tokai Univ, ⁷AbbVie, ⁸Shinrakuen Hosp). Comparison of paricalcitol with maxacalcitol injection in Japanese hemodialysis patients with secondary hyperparathyroidism. *Ther Apher Dial.* 2015; **19**: 225-34. Epub 2014 Nov 3.

Takahara Y¹, Matsuda Y¹, Takahashi S¹, Shigematsu T² (Bayer Yakuhin, Ltd., ²Wakayama Med Univ); Lanthanum Carbonate Study Group. Efficacy and safety of lanthanum carbonate in pre-dialysis CKD patients with hyperphosphatemia: a randomized trial. *Clin Nephrol.* 2014; **82**: 181-90.

Shibagaki Y¹, Ohno I, Hosoya T, Kimura K¹ (St. Marianna Univ Sch Med). Safety, efficacy and renal effect of febuxostat in patients with moderate-to-severe kidney dysfunction. *Hypertens Res.* 2014; **37**: 919-25.